 Westport, Connecticut--Newsfile Corp. - June 23, 2021 - Portage Biotech Inc. NASDAQ: PRTG Portage or the Company a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that it has commenced an underwritten public offering of its ordinary shares. In addition, Portage expects to grant the underwriters a 30-day option to purchase up to an additional 15 of the number of the ordinary shares sold in connection... 